In a previous study we demonstrated—by using selective PPARγ activators and repressors in vitro and organ-specific PPARγ knock-out mice in vivo—that adipose and hepatic PPARγ are critical mediators of the beneficial effects of SCFA on the metabolic syndrome, with clearly distinct and complementary roles [13]. The gene discussed is PPARG; the disease is metabolic syndrome.